Hutchmed and AstraZeneca have commenced an international Phase III SAMETA clinical trial of oral therapy, savolitinib, along with Imfinzi (durvalumab) to treat patients with advanced papillary renal cell carcinoma (PRCC), a kidney cancer subtype.

The open-label, controlled, randomised trial will evaluate the combination therapy in MET-driven advanced PRCC patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The companies noted that they have administered the first dose to the first patient last week.

Marketed as Orpathys in China, savolitinib is a greatly selective small-molecule MET tyrosine kinase inhibitor while AstraZeneca’s Imfinzi is an inhibitor of programmed death-ligand 1.

The Phase III trial will analyse the safety and efficacy of the savolitinib and Imfinzi combination as against either the Imfinzi or Sutent (sunitinib) monotherapy.

An oral inhibitor of multi-kinase, Sutent is regarded as the standard of care therapy for PRCC.

Subjects who have MET-driven, unresectable and locally advanced or metastatic PRCC and have not received any therapy so far will be enrolled in the trial.

Median progression-free survival (PFS) is the trial’s primary goal.

Additional goals include objective response rate, median overall survival, duration of response, time to the second progression, disease control rate at six months and one year, pharmacokinetics, safety and quality of life.

AstraZeneca and HUTCHMED signed an international licensing deal in 2011 to co-develop and co-market savolitinib.

Under the deal, HUTCHMED agreed to the drug’s development in China while AstraZeneca oversees the activities outside the country.

Savolitinib is currently marketed in China to treat non-small cell lung cancer patients who have MET exon 14 skipping alterations and have progressed after receiving previous systemic treatment or could not undergo chemotherapy.

Furthermore, the drug is being analysed to treat various kinds of tumours, including those affecting lung, kidney, and gastric cancers, as monotherapy and in combination with other treatments.

In July 2021, HUTCHMED started a Phase I trial of its oral treatment, HMPL‑295, for treating advanced malignant solid tumour patients.